Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.37 USD
Change Today -0.11 / -0.36%
Volume 488.5K
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Open
$30.78
Previous Close
$30.48
Day High
$30.89
Day Low
$30.04
52 Week High
01/13/15 - $45.45
52 Week Low
08/1/14 - $28.26
Market Cap
1.3B
Average Volume 10 Days
616.7K
EPS TTM
$0.64
Shares Outstanding
42.8M
EX-Date
--
P/E TM
47.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACORDA THERAPEUTICS INC (ACOR)

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. The company also markets Ampyra as Fampyra in Europe, Asia, and the Americas. It is also involved in developing CVT-301, which is in Phase III clinical trial for the treatment of OFF episodes in Parkinson’s disease; Dalfampridine that is in Phase III clinical trial for the treatment of chronic post-stroke deficits; Neuregulin Program, which is in Phase Ib clinical trial for the treatment of heart failure; CVT-427 that is in pre-clinical development for the treatment of migraines; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury, as well as developing Plumiaz, a proprietary nasal spray formulation of diazepam for the treatment of people with epilepsy. The company has a collaboration agreement with Biogen Idec International GmbH for the development and commercialization of products containing aminopyridines. The company was founded in 1995 and is headquartered in Ardsley, New York.

489 Employees
Last Reported Date: 02/27/15
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $745.8K
Chief Financial Officer
Total Annual Compensation: $428.3K
Chief of Business Operations
Total Annual Compensation: $312.7K
President of International, General Counsel a...
Total Annual Compensation: $555.5K
Chief Medical Officer
Total Annual Compensation: $434.0K
Compensation as of Fiscal Year 2014.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Provides an Update on the Status of its PLUMIAZTM (Diazepam) Nasal Spray Program

On May 27, 2015, Acorda Therapeutics, Inc. provided an update on the status of its PLUMIAZTM (diazepam) Nasal Spray program. The Company has completed discussions with the U.S. Food and Drug Administration (FDA), and is advancing the development of PLUMIAZ. Based on interactions with the FDA, the Company plans to conduct three clinical trials prior to resubmitting the New Drug Application (NDA) for PLUMIAZ. The first trial, a long-term open-label study assessing safety and tolerability of PLUMIAZ over 52 weeks, was initiated in December 2014. This study will enroll approximately 100 participants ages 12-65 and is expected to be completed in the second half of 2016. The Company will also conduct a pharmacokinetic dose proportionality study in healthy adults; this study is expected to be initiated in the third quarter of 2015 and completed in first half of 2016. The third study will assess the bioavailability, safety and tolerability of PLUMIAZ compared to diazepam rectal gel (Diastat®). This open-label, randomized, crossover study will enroll approximately 120 people with refractory epilepsy ages 12-65 who experience seizure clusters. This study is expected to be initiated in the second quarter of 2015 and completed in the fourth quarter of 2016. Pending the successful completion of these studies, the Company is planning to resubmit its NDA for PLUMIAZ in the first quarter of 2017. Based on FDA guidelines, the expected review period of the resubmitted NDA would be six months. If approved, the Company projects peak U.S. net sales revenue of more than $200 million. Previously, the Company estimated peak sales of more than $100 million; the increase is based on the unmet need in this market and expanding the clinical trial program to include adolescents. PLUMIAZ has orphan-drug designation. PLUMIAZ is being studied as a potential treatment for the management of selected, refractory patients with epilepsy currently on stable regimens of antiepileptic drugs (AEDs) who experience bouts of increased seizure activity. These bouts of increased seizure activity are also known as seizure clusters or acute repetitive seizures (ARS).

Acorda Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 03:40 PM

Acorda Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Michael W. Rogers, Chief Financial Officer.

Acorda Therapeutics, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM

Acorda Therapeutics, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM. Venue: Time Warner Center, New York, United States. Speakers: Jane Wasman, President of International, General Counsel and Corporate Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $30.37 USD -0.11

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $41.29 USD +0.09
Depomed Inc $21.33 USD +0.47
Durect Corp $2.60 USD 0.00
Impax Laboratories Inc $48.90 USD +1.89
Isis Pharmaceuticals Inc $66.94 USD -0.38
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 93.3x
Price/Sales 3.0x
Price/Book 2.4x
Price/Cash Flow 93.9x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit www.acorda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.